Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Creatine does not cause hair loss, but it may accelerate hair loss in those predisposed to male pattern baldness. Finasteride users report mixed experiences with creatine, with some noticing no change and others experiencing increased shedding.

Switching from finasteride to dutasteride often causes increased hair shedding initially. Dutasteride is stronger but takes longer to show results, leading to concerns about worsening hair loss during the transition.

Finasteride can reduce semen volume due to prostate shrinkage but doesn't affect fertility. To increase semen volume, consider zinc, lecithin, and reducing finasteride dosage.

Finasteride and minoxidil are commonly recommended by hair transplant clinics, including those in Turkey, despite some negative perceptions and concerns about side effects. The conversation highlights differing opinions on the effectiveness and safety of these treatments, with some users expressing skepticism about side effects and others emphasizing the importance of these medications for successful hair transplants.

Finasteride increased testosterone and estrogen, stopped hair loss, and promoted regrowth. Users discussed side effects like libido changes and considered adding minoxidil and aromatase inhibitors.

The user experienced significant hair growth using topical finasteride and minoxidil but noticed nipple changes, suggesting early gynecomastia. They plan to stop the treatment and consider blood work to check hormonal balance.

Nizoral shampoo caused significant hair thinning and oiliness for some users, while others found it beneficial for slowing hair loss. The original poster experienced negative effects and was advised to stop using Nizoral and switch to a gentler shampoo.

Finasteride is effective in promoting hair growth and reversing hair miniaturization in men with androgenetic alopecia, with improvements seen in various studies over different durations. Some users report initial side effects like ball ache, which often resolve as the body adjusts.

Finasteride and dutasteride may increase estrogen levels, leading to water retention and a fuller face. Users discuss managing these effects with lifestyle changes and supplements like zinc and DIM.

The user has been using a combination of oral finasteride, oral dutasteride, topical and oral minoxidil, microneedling, and keto shampoo for hair loss, experiencing significant shedding recently. Suggestions include simplifying the regimen by dropping finasteride and topical minoxidil, and possibly adding RU58841, while others advise maintaining the current approach for consistent results.

A 44-year-old man experienced significant hair regrowth after switching from topical to 1.25mg oral minoxidil and 0.5mg daily finasteride, with no side effects. He noticed hair thickening after two months and credits the oral form's effectiveness.

Increased coffee intake might be linked to hair shedding, but the cause is unclear. The user is on finasteride and has increased water intake, possibly affecting electrolyte balance.

Diet and specific shampoo improved scalp health and hair regrowth for someone with seborrheic dermatitis, while medications like Minoxidil and finasteride had no effect. A low-sugar, keto diet was key to their success.

A user has been on dutasteride for nearly 2 years with no improvement in hair loss, expressing frustration. Other users suggest checking for other health conditions, getting bloodwork, and considering stopping TRT or trying finasteride.

A user tried microneedling for hair loss with a Dr. Pen at 0.8 mm and experienced bleeding, questioning if the intensity was too much. Others suggested a less aggressive approach, and one mentioned finasteride as a helpful treatment without side effects.

Hair loss may be influenced more by inflammation, microbiome imbalances, and gut health than DHT. Treatments discussed include minoxidil, finasteride, RU58841, fecal microbiota transplants, and JAK inhibitors.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

The user is experiencing a difficult shedding phase after starting a hair loss treatment with oral finasteride, topical minoxidil, and microneedling. Despite the shedding, they remain hopeful for regrowth and plan to continue the treatment, encouraged by others' positive results.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user is using finasteride and topical minoxidil for hair loss after previously trying them separately without success. They are experiencing a shedding phase but are committed to the treatment.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

The conversation is about hair loss treatment progress using oral finasteride, topical minoxidil, and microneedling. Users discuss experiencing shedding phases and the importance of trusting the process for hair regrowth.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

The shed phase from using finasteride and minoxidil can vary, with some experiencing noticeable hair loss and others having minimal shedding. Despite initial shedding, many users report eventual hair regrowth and improvement, making the treatment worthwhile.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

Phase 3 for PP405 will start in 2027, disappointing many who expected it this year. Some users are trying treatments like topical minoxidil and topical dutasteride while waiting for new developments.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.